Читать книгу Sarcopenia - Группа авторов - Страница 16

This organization conveyed American and European researchers to develop a definition of sarcopenia that could be a meaningful surrogate for clinically useful endpoints, allow for treatments, include only measurements longitudinally linked to meaningful outcomes, and have definable cut‐off points based on the data [10]. Deviating from the other groups, it was decided that “sarcopenia with limited mobility” would be the preferred term to define persons with a need for therapeutic interventions. Sarcopenia with limited mobility was defined as a muscle loss associated with a slow walking speed, with an approach that mirrored that proposed by ESPEN. The limitation in mobility should not be clearly attributable to the direct effect of specific diseases such as peripheral vascular disease, or central or peripheral nervous system disorders, dementia, or cachexia. This group left the question open of whether sarcopenia as a term should be limited to use in older persons or used as a general term for adults of any age.